Home
About
Overview
Sharing Data
ORCID
Help
History (3)
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Patterns of common illness and injury of readymade garment workers and a review of safety practices in Bangladesh.
Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013.
See All 3 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77.
View in:
PubMed
subject areas
Adult
Antibodies, Monoclonal
Crohn Disease
Female
Follow-Up Studies
Humans
Induction Chemotherapy
Maintenance Chemotherapy
Male
Middle Aged
Remission Induction
Time Factors
Treatment Outcome
Ustekinumab
authors with profiles
Stephen B. Hanauer